<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00702585</url>
  </required_header>
  <id_info>
    <org_study_id>P07016</org_study_id>
    <secondary_id>38805</secondary_id>
    <nct_id>NCT00702585</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Optimal Dose of Org 36286 to Induce Monofollicular Ovulation in Women With WHO Group II Anovulatory Infertility (P07016)</brief_title>
  <official_title>A Phase II, Randomized, Double-blind, Placebo-controlled, Comparative Trial to Investigate the Optimal Dose of a Single Administration of Org 36286 (Corifollitropin Alfa) to Induce Monofollicular Ovulation in Women With WHO Group II Anovulatory Infertility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this trial were to investigate the feasibility and the optimal dose of a&#xD;
      single administration of Org 36286 to induce monofollicular ovulation in women with WHO Group&#xD;
      II anovulatory infertility and to assess the safety (including the absence of antibody&#xD;
      formation) of Org 36286.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a phase II, randomized, double-blind, placebo controlled, comparative trial to&#xD;
      investigate the optimal dose of a single administration of Org 36286 to induce monofollicular&#xD;
      ovulation in women with WHO Group II anovulatory infertility.&#xD;
&#xD;
      Treatment injection was given on Day 1-3 after the onset of a spontaneous or progestagen&#xD;
      induced withdrawal bleeding. After injection, ultrasound monitoring and sampling for serum&#xD;
      hormones were done on treatment Days 3, 5, and daily from Day 7 to 21 or until a urinary&#xD;
      luteinizing hormone (LH) peak was detected. From treatment Day 7 the urinary LH response was&#xD;
      assessed to detect the preovulatory LH peak. In case of hyperstimulation, production of&#xD;
      endogenous gonadotropins could be suppressed by giving daily injections of GnRH antagonist.&#xD;
&#xD;
      Post-treatment assessments were done in the third week after the urinary LH peak. If no LH&#xD;
      peak was detected, posttreatment assessments were performed four to five weeks after Org&#xD;
      36286 or placebo injection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2001</start_date>
  <completion_date type="Actual">October 15, 2002</completion_date>
  <primary_completion_date type="Actual">October 15, 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant Ovulation Rate in Monofollicular Cycles</measure>
    <time_frame>Up to 2 Weeks Following LH Peak</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participant Overall Ovulation Rate</measure>
    <time_frame>Up to 2 Weeks Following LH Pek</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cancellation of Menstrual Cycle</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Follicle Size</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Miscarriages, Biochemical, Ectopic, Clinical, Vital, Single, or Multiple Ongoing Pregnancies</measure>
    <time_frame>Up to 10 Weeks Following Ovulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 10 Weeks Following Ovulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Laboratory Abnormalities</measure>
    <time_frame>Up to 3 Weeks Following Ovulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Vital Signs</measure>
    <time_frame>Up to 3 Weeks Followiing Ovulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Antibodies to Org 36286</measure>
    <time_frame>Up to 3 Weeks Following Ovulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Serum Follicle Stimulating Hormone (FSH) Level</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Serum LH Level</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Inhibin-B, E2, and P Serum Concentration</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Ovarian Hyperstimulation Syndrome (OHSS)</measure>
    <time_frame>Up to 2 Weeks Following LH Peak</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Org 36286 7.5 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Org 36286 7.5 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Org 36286 15 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Org 36286 15 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Org 36286 30 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Org 36286 30 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Org 36286 60 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Org 36286 60 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to Org 36286 administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Org 36286</intervention_name>
    <description>Org 36286 single-dose subcutaneous injection</description>
    <arm_group_label>Org 36286 15 µg</arm_group_label>
    <arm_group_label>Org 36286 30 µg</arm_group_label>
    <arm_group_label>Org 36286 60 µg</arm_group_label>
    <arm_group_label>Org 36286 7.5 µg</arm_group_label>
    <other_name>Corifollitropin alpha</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to Org 36286 as a single-dose subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Wish to conceive;&#xD;
&#xD;
          -  Oligomenorrhea (cycle length &gt;=41 days) or amenorrhea (no menstrual cycle for &gt;6&#xD;
             months);&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt;=18 and &lt;=32 kg/m^2;&#xD;
&#xD;
          -  Serum FSH levels within normal limits (1-10 IU/L);&#xD;
&#xD;
          -  Normal serum prolactin and thyroid stimulating hormone (TSH) levels;&#xD;
&#xD;
          -  Progestagen induced withdrawal bleeding or spontaneous menstrual bleeding;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumours of the ovary, breast, uterus, pituitary or hypothalamus;&#xD;
&#xD;
          -  Pregnancy or lactation;&#xD;
&#xD;
          -  Undiagnosed vaginal bleeding;&#xD;
&#xD;
          -  Ovarian cysts or enlarged ovaries not related to polycystic ovarian disease (PCOD);&#xD;
&#xD;
          -  Any ovarian and/or abdominal abnormality interfering with ultrasound examination;&#xD;
&#xD;
          -  Malformations of the sexual organs incompatible with pregnancy;&#xD;
&#xD;
          -  Clomiphene resistance with documented anovulation (treated with 150 mg clomiphene for&#xD;
             five days and no ovulation);&#xD;
&#xD;
          -  Treatment with metformin, gonadotropins, or GnRH analogs within 90 days prior to the&#xD;
             start of Org 36286 treatment;&#xD;
&#xD;
          -  Treatment with clomiphene citrate within 42 days prior to the start of Org 36286&#xD;
             treatment;&#xD;
&#xD;
          -  Alcohol or drug abuse within the 12 months preceding signing of informed consent;&#xD;
&#xD;
          -  Any clinically relevant abnormal laboratory value;&#xD;
&#xD;
          -  Hypersensitivity to any of the substances in Org 36286;&#xD;
&#xD;
          -  Hypersensitivity to Orgalutran® or any of its components;&#xD;
&#xD;
          -  Use of any investigational drugs during 90 days before screening or previous&#xD;
             participation in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Balen AH, Mulders AG, Fauser BC, Schoot BC, Renier MA, Devroey P, Struijs MJ, Mannaerts BM. Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility. J Clin Endocrinol Metab. 2004 Dec;89(12):6297-304.</citation>
    <PMID>15579793</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 18, 2008</study_first_submitted>
  <study_first_submitted_qc>June 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2008</study_first_posted>
  <last_update_submitted>November 8, 2019</last_update_submitted>
  <last_update_submitted_qc>November 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovulation Induction</keyword>
  <keyword>Pharmacological effects of drugs</keyword>
  <keyword>Hormones</keyword>
  <keyword>Hormone substitutes and Hormone Antagonists</keyword>
  <keyword>Pharmacological Actions</keyword>
  <keyword>Randomized</keyword>
  <keyword>Multi-center</keyword>
  <keyword>Multi-national</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

